Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort

Background Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with advanced MCC (aMCC) in clinical trials. To date, o...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sonja Levy, Dirk Grünhagen, Maureen J B Aarts, Ferry A L M Eskens, Kristien B M I Keymeulen, Lukas B Been, Alexander van Akkooi, Mathilde Jalving, Margot E T Tesselaar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2020-10-01
Edice:	Journal for ImmunoTherapy of Cancer
On-line přístup:	https://jitc.bmj.com/content/8/2/e001076.full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!